WO2008126920A1 - 糖尿病治療薬 - Google Patents

糖尿病治療薬 Download PDF

Info

Publication number
WO2008126920A1
WO2008126920A1 PCT/JP2008/057185 JP2008057185W WO2008126920A1 WO 2008126920 A1 WO2008126920 A1 WO 2008126920A1 JP 2008057185 W JP2008057185 W JP 2008057185W WO 2008126920 A1 WO2008126920 A1 WO 2008126920A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
remedy
diabetes
hypoglycemic
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/057185
Other languages
English (en)
French (fr)
Inventor
Naoyuki Fukuchi
Satoru Okamoto
Wataru Miyanaga
Sen Takeshita
Masaru Takayanagi
Yumiko Fukuda
Takao Ikenoue
Naoyuki Yamada
Naoko Arashida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to EP08740282A priority Critical patent/EP2157092A4/en
Priority to JP2009509382A priority patent/JP5672699B2/ja
Publication of WO2008126920A1 publication Critical patent/WO2008126920A1/ja
Priority to US12/574,947 priority patent/US8357680B2/en
Anticipated expiration legal-status Critical
Priority to US13/709,798 priority patent/US8772281B2/en
Priority to US14/261,953 priority patent/US9440980B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)

Abstract

　本発明は、血糖降下作用を有する化合物（以下、「血糖降下作用化合物」と いう）のスクリーニング法、新規な作用メカニズムを有する化合物を含有する糖尿病治療 薬などに関する。より詳しくは、本発明は３量体GTP結合蛋白質βサブユニットに結合す る血糖降下作用化合物のスクリーニング法、３量体GTP結合蛋白質βサブユニットに結合 することを特徴とする血糖降下作用化合物を有効成分とする糖尿病治療薬などに関する。
PCT/JP2008/057185 2007-04-11 2008-04-11 糖尿病治療薬 Ceased WO2008126920A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP08740282A EP2157092A4 (en) 2007-04-11 2008-04-11 Remedy for diabetes
JP2009509382A JP5672699B2 (ja) 2007-04-11 2008-04-11 血糖降下作用化合物のスクリーニング法
US12/574,947 US8357680B2 (en) 2007-04-11 2009-10-07 Remedy for diabetes
US13/709,798 US8772281B2 (en) 2007-04-11 2012-12-10 Remedy for diabetes
US14/261,953 US9440980B2 (en) 2007-04-11 2014-04-25 Remedy for diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007104085 2007-04-11
JP2007-104085 2007-04-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/574,947 Continuation US8357680B2 (en) 2007-04-11 2009-10-07 Remedy for diabetes

Publications (1)

Publication Number Publication Date
WO2008126920A1 true WO2008126920A1 (ja) 2008-10-23

Family

ID=39864015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057185 Ceased WO2008126920A1 (ja) 2007-04-11 2008-04-11 糖尿病治療薬

Country Status (4)

Country Link
US (3) US8357680B2 (ja)
EP (1) EP2157092A4 (ja)
JP (2) JP5672699B2 (ja)
WO (1) WO2008126920A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20130130277A1 (en) * 2007-04-11 2013-05-23 Ajinomoto Co., Inc. Remedy for diabetes
JPWO2016104441A1 (ja) * 2014-12-22 2017-10-05 Ｅａファーマ株式会社 角膜上皮障害治療剤

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053266A1 (en) 2000-01-24 2001-07-26 Kinacia Pty Ltd. Therapeutic morpholino-substituted compounds
WO2002044180A1 (en) 2000-12-01 2002-06-06 Ajinomoto Co.,Inc. Lactam compounds and medicinal use thereof
WO2004069259A1 (ja) * 2003-02-07 2004-08-19 Ajinomoto Co., Inc. 糖尿病治療剤
WO2005042536A1 (ja) 2003-10-31 2005-05-12 Ajinomoto Co., Inc. 複素環を有する新規縮合多環式化合物及びその医薬用途
WO2005068467A1 (ja) 2004-01-14 2005-07-28 Ajinomoto Co., Inc. 新規縮環化合物
WO2006118341A1 (ja) 2005-04-28 2006-11-09 Ajinomoto Co., Inc. 新規ラクタム化合物
WO2007020853A1 (ja) * 2005-08-12 2007-02-22 Astellas Pharma Inc. 薬剤の標的蛋白質を同定する方法及び標的蛋白質を用いた糖尿病治療薬のスクリーニング方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003278342A1 (en) 2002-11-18 2004-06-15 Arm Limited Security mode switching via an exception vector
WO2008103382A1 (en) * 2007-02-20 2008-08-28 Sergey Kozmin Method for assembling high-purity chemical libraries, compounds suppressing acetyl coenzyme a carboxylase activities discovered by same
JP5672699B2 (ja) * 2007-04-11 2015-02-18 味の素株式会社 血糖降下作用化合物のスクリーニング法
RS52270B (sr) * 2007-12-20 2012-10-31 Bayer Pharma Aktiengesellschaft 4-(4-cijano-2-tioaril)-dihidropirimidinon i njegova primena

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053266A1 (en) 2000-01-24 2001-07-26 Kinacia Pty Ltd. Therapeutic morpholino-substituted compounds
WO2002044180A1 (en) 2000-12-01 2002-06-06 Ajinomoto Co.,Inc. Lactam compounds and medicinal use thereof
WO2004069259A1 (ja) * 2003-02-07 2004-08-19 Ajinomoto Co., Inc. 糖尿病治療剤
WO2005042536A1 (ja) 2003-10-31 2005-05-12 Ajinomoto Co., Inc. 複素環を有する新規縮合多環式化合物及びその医薬用途
WO2005068467A1 (ja) 2004-01-14 2005-07-28 Ajinomoto Co., Inc. 新規縮環化合物
WO2006118341A1 (ja) 2005-04-28 2006-11-09 Ajinomoto Co., Inc. 新規ラクタム化合物
WO2007020853A1 (ja) * 2005-08-12 2007-02-22 Astellas Pharma Inc. 薬剤の標的蛋白質を同定する方法及び標的蛋白質を用いた糖尿病治療薬のスクリーニング方法

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
ASANO ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, 2000, pages 17671
BONACCI ET AL., SCIENCE, vol. 312, 2006, pages 443
CHO ET AL., ANNUAL REVIEWS OF BIOPHYSICAL BIOMOLECULAR STRUCTURE, vol. 34, 2005, pages 119
DAVIS ET AL., BIOCHEMISTRY, vol. 44, 2005, pages 10593
DOWLER ET AL., SCIENCE STKE, vol. L6, 2002
HAJDUCH ET AL., FEBS LETTERS, vol. 492, 2001, pages 199
HAZEKI O. ET AL.: "Activation of PI 3-kinase by G protein beta gamma subunits", LIFE SCIENCE, vol. 62, no. 17/18, 1998, pages 1555 - 1559, XP008121366 *
HIROSHI KUBO ET AL.: "Specific role of p85/p110beta in GTP-binding protein-mediated activation of Akt-1", DAI 78 KAI THE JAPANESE BIOCHEMICAL SOCIETY TAIKAI HAPPYO SHOROKUSHU, 25 August 2005 (2005-08-25), pages 931 + ABSTR. NO. 3P-368, XP008116987 *
HONGJIE CHEN ET AL.: "Insulin signaling in vascular endothelial cells: a key role for heterotrimeric G proteins revealed by siRNA-mediated Gbeta1 knockdown", BIOCHEMISTRY, vol. 45, 2006, pages 8023 - 8033, XP008121367 *
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, 2004, pages 44554
KERCHNER ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, 2004, pages 44554
KNIGHT ET AL., BIOORGANIC & MEDICINAL CHEMISTRY, vol. 12, 2004, pages 4749
KOZASA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, 1995, pages 1734
LEOPOLDT ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, 1998, pages 7024
MAIER ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 1999, pages 29311
SCOTT ET AL., EMBO JOURNAL, vol. 20, 2001, pages 767
See also references of EP2157092A4 *
SHEEHAN ET AL., CLINICAL MEDICINE & RESEARCH, vol. 1, 2003, pages 189
SIMPSON ET AL., ANNUAL REVIEW OF BIOCHEMISTRY, vol. 55, 1986, pages 1059
STEMWEIS ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 259, 1984, pages 13806
WETTSCHURECK ET AL., PHYSIOLOGICAL REVIEWS, vol. 85, 2005, pages 1159
YOSHINORI KANOH ET AL.: "Effect of pertussis toxin on insulin-induced signal transduction in rat adipocytes and soleus muscles", CELLULAR SIGNALLING, vol. 12, no. 4, 2000, pages 223 - 232, XP008121365 *
ZHANG ET AL., JOURNAL OF BIOMOLECULAR SCREENING, vol. 4, 1999, pages 67

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130130277A1 (en) * 2007-04-11 2013-05-23 Ajinomoto Co., Inc. Remedy for diabetes
US8772281B2 (en) * 2007-04-11 2014-07-08 Ajinomoto Co., Inc. Remedy for diabetes
US20140309135A1 (en) * 2007-04-11 2014-10-16 Ajinomoto Co., Inc. Remedy for diabetes
US9440980B2 (en) 2007-04-11 2016-09-13 Ea Pharma Co., Ltd. Remedy for diabetes
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JPWO2016104441A1 (ja) * 2014-12-22 2017-10-05 Ｅａファーマ株式会社 角膜上皮障害治療剤

Also Published As

Publication number Publication date
EP2157092A1 (en) 2010-02-24
JPWO2008126920A1 (ja) 2010-07-22
US8357680B2 (en) 2013-01-22
EP2157092A4 (en) 2011-04-13
JP5742900B2 (ja) 2015-07-01
JP2014012708A (ja) 2014-01-23
US8772281B2 (en) 2014-07-08
US20100093055A1 (en) 2010-04-15
US20140309135A1 (en) 2014-10-16
JP5672699B2 (ja) 2015-02-18
US20130130277A1 (en) 2013-05-23
US9440980B2 (en) 2016-09-13

Similar Documents

Publication Publication Date Title
WO2007003962A3 (en) Gpcr agonists
WO2007003961A3 (en) Gpcr agonists
WO2007133653A3 (en) Methods for treating blood disorders
CL2008001049A1 (es) Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
WO2009041705A3 (en) 5-membered heterocyclic compounds as proton pump inhibitors
CL2007002187A1 (es) Compuestos derivados espirocetal sustituidos; composicion farmaceutica que comprende a dicho compuesto; y su uso para el tratamiento de la diabetes, hiperglicemia, complicaciones diabeticas y obesidad.
WO2008001931A3 (en) Fused cyclic compounds
WO2009121939A3 (en) C-aryl glycoside compounds for the treatment of diabetes and obesity
CL2008002424A1 (es) Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido; y uso de la composicion farmaceutica para el tratamiento de la diabetes mellitus, tolerancia anormal a la glucosa e hiperglucemia, trastornos metabolicos, entre otras.
WO2008108958A8 (en) Benzimidazole derivatives and methods of use thereof
CL2007002186A1 (es) Compuestos derivados espirocetal sustituidos de anillo fusionado; composicion farmaceutica que comprende a dicho compuesto; y uso de la composicion para el tratamiento de la diabetes, hiperglicemia, complicaciones diabeticas y obesidad.
WO2009044774A1 (ja) インターロイキン６受容体阻害剤を有効成分とする移植片対宿主病治療剤
WO2010056022A3 (en) Melanocortin receptor agonists
WO2009049716A3 (en) Novel fungicides
WO2007114945A3 (en) Compositions and methods for enhancing the antioxidant status of animals
WO2009003649A3 (de) Akarizide wirkstoffkombinationen
WO2010049454A3 (en) Antimicrobial composition from copepods
WO2008128639A8 (de) Thiadiazolyloxyphenylamidine und deren verwendung als fungizide
WO2008049053A3 (en) Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
AU2007259257A8 (en) Antitumoral dihydropyran-2-one compounds
WO2008136392A1 (ja) 経口投与用製剤
WO2005121078A3 (de) Substituierte cyclopenten-verbindungen
WO2007119116A3 (en) Improved synthesis and preparations of duloxetine salts
WO2009000533A8 (en) Novel herbicides
WO2006058628A3 (en) Substituted benzoquinolizines as dpp-iv inhibitors for the treatment of diabetes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740282

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009509382

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008740282

Country of ref document: EP